← board
MEIP
distress 5/10 · elevated risk$1.07-3%today-19% from 52w high
Revenue
pre-revenue
Liquidity
$8M
Runway
0.4 yrs
Shares 1y
—
Price & events
-18.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-8.5%
1W
-10.1%
1M
-3.6%
3M
—
6M
—
1Y
—
2Y
—
5Y
-18.9%
All
Overview
- Volume
- 865.40K
- 52 Week Range
- $0.95 – $1.32
- RVOL
- 2.56x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-09-28earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-07-23Laidlaw & Co.Buy → Hold
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.